Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Bio-Rad Laboratories (BIO)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$369.00-2.89%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.50 → 10.25 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for BIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in operational efficiency driven by activist involvement | Activist involvement could improve efficiency and unlock value. | Improving | No meaningful operational improvements reported within 2 quarters | Qualitative: $30M-$35M cost savings target & 10-12% margin goal reaffirmed Bio-Rad reaffirmed 10-12% margin targets and $30M-$35M cost savings goals following activist involvement and workforce reductions. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BIO is a recent-performance-led business with a cyclical risk profile, not a clear growth story today. Its multi-year view remains intact, supported by strong recent performance and a more favorable sector backdrop, while execution on growth and margins is still mixed.
Valuation is tagged as justified, with expectations closely aligned to the model and a modest premium versus peers. That suggests the market already recognizes the current setup, while the evidence does not point to a large expectations gap or obvious valuation fragility.
Near term, recent results have been strong overall, including an August earnings beat, but BIO also missed in April and has a history of recent misses. For 2026, management has lowered its revenue-growth range to -3.0% to 0.5% and expects operating margin below 2025’s 12.5%, so near-term progress may remain limited despite restructuring efforts.
The multi-year view depends on whether BIO can meet its revised revenue and margin goals while restructuring costs and workforce changes are managed. A guidance cut or further weakening in jobs data would add pressure, while continued strength from healthcare peers could support the sector backdrop.
Over the next 1 to 3 years, BIO has a supported but mixed thesis: recent performance and sector conditions are favorable, while modest growth, lower margin expectations, and execution risk remain central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company targets an operating margin near 11%, despite recent margin cuts. |
| Under Pressure |
| Operating margin falls below 10.0% in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 4 supplied quarters. Management reported: “Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives.” “Full-Year 2026 Financial Outlook For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.” Operating income was $72.600 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Revenue growth between -3.0% and 0.5% in fiscal 2026 | A primary condition in Bio-Rad Laboratories's published investment case. The stated target is between -3.0% and 0.5% YoY. | Intact | YoY revenue growth falls below -3.0% in FY26 | Revenue growth: 0.52% FY2026-Q3; GAAP. Published target: between -3.0% and 0.5% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20260.520674 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$9.72 → $10.25 · observed estimates
$2.63B → $2.67B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-25 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-26 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-27 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-28 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-29 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-30 | $9.72 | $2,634,795,700 | 5 / 5 |
| 2026-07-31 | $9.96 | $2,660,612,338 | 2 / 4 |
| 2026-08-01 | $9.72 | $2,634,888,500 | 5 / 5 |
| 2026-08-02 | $9.72 | $2,634,888,500 | 5 / 5 |
| 2026-08-03 | $9.72 | $2,634,888,500 | 5 / 5 |
| 2026-08-04 | $9.72 | $2,634,888,500 | 5 / 5 |
| 2026-08-05 | $9.72 | $2,634,888,500 | 5 / 5 |
| 2026-08-06 | $9.96 | $2,660,612,338 | 2 / 4 |
| 2026-08-07 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-08 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-09 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-10 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-11 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-12 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-13 | $10.03 | $2,633,495,220 | 5 / 5 |
| 2026-08-14 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-15 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-16 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-17 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-18 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-19 | $10.35 | $2,658,871,997 | 2 / 4 |
| 2026-08-20 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-21 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-22 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-23 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-24 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-25 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-26 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-27 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-28 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-29 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-30 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-08-31 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-01 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-02 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-03 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-04 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-05 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-06 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-07 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-08 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-09 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-10 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-11 | $10.35 | $2,658,869,023 | 2 / 4 |
| 2026-09-12 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-13 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-14 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-15 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-16 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-17 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-18 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-19 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-20 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-21 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-22 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-23 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-24 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-25 | $10.35 | $2,658,861,720 | 2 / 4 |
| 2026-09-26 | $10.35 | $2,658,861,720 | 2 / 3 |
| 2026-09-27 | $10.35 | $2,658,861,720 | 2 / 3 |
| 2026-09-28 | $10.35 | $2,658,861,720 | 2 / 3 |
| 2026-09-29 | $10.56 | $2,666,123,597 | 2 / 3 |
| 2026-09-30 | $10.56 | $2,666,123,597 | 2 / 3 |
| 2026-10-01 | $10.56 | $2,666,123,597 | 2 / 2 |
| 2026-10-02 | $10.56 | $2,666,123,597 | 2 / 2 |
| 2026-10-03 | $10.56 | $2,666,123,597 | 2 / 2 |
| 2026-10-04 | $10.56 | $2,666,123,597 | 2 / 2 |
| 2026-10-05 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-06 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-07 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-08 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-09 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-10 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-11 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-12 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-13 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-14 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-15 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-16 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-17 | $10.50 | $2,670,485,395 | 2 / 2 |
| 2026-10-18 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-19 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-20 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-21 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-22 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-23 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-24 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-25 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-26 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-27 | $10.24 | $2,670,500,000 | 2 / 2 |
| 2026-10-28 | $10.25 | $2,670,485,395 | 2 / 2 |
| 2026-10-29 | $10.25 | $2,670,485,395 | 2 / 2 |
| 2026-10-30 | $10.25 | $2,670,485,395 | 2 / 2 |
| 2026-10-31 | $10.25 | $2,670,485,395 | 1 / 2 |
| 2026-11-01 | $10.25 | $2,670,485,395 | 1 / 2 |
| 2026-11-02 | $10.25 | $2,670,485,395 | 1 / 2 |
| 2026-11-03 | $10.25 | $2,670,485,395 | 1 / 2 |
| 2026-11-04 | $10.25 | $2,670,485,395 | 1 / 2 |
| 2026-11-05 | $10.25 | $2,670,485,395 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.